Recombinant
RabMAb

Anti-Cytokeratin 10 antibody [SP99] - C-terminal (ab183317)

Overview

  • Product name
    Anti-Cytokeratin 10 antibody [SP99] - C-terminal
    See all Cytokeratin 10 primary antibodies
  • Description
    Rabbit monoclonal [SP99] to Cytokeratin 10 - C-terminal
  • Host species
    Rabbit
  • Tested applications
    Suitable for: IHC-Pmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Cow, Dog
  • Immunogen

    Synthetic peptide within Human Cytokeratin 10 (C terminal). The exact sequence is proprietary.
    Database link: P13645

  • Positive control
    • Human skin, skin squamous cell carcinoma, cervical squamous cell carcinoma tissues
  • General notes

     

     

    This product is a recombinant rabbit monoclonal antibody.

Properties

  • Form
    Liquid
  • Storage instructions
    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
  • Storage buffer
    pH: 7.60
    Preservative: 0.1% Sodium azide
    Constituents: 1% BSA, 98% PBS
  • Concentration information loading...
  • Purification notes
    Purified from TCS by protein A/G.
  • Clonality
    Monoclonal
  • Clone number
    SP99
  • Isotype
    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab183317 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/1000.

Antigen retrieval not required

Target

  • Tissue specificity
    Seen in all suprabasal cell layers including stratum corneum.
  • Involvement in disease
    Defects in KRT10 are a cause of bullous congenital ichthyosiform erythroderma (BCIE) [MIM:113800]; also known as epidermolytic hyperkeratosis (EHK) or bullous erythroderma ichthyosiformis congenita of Brocq. BCIE is an autosomal dominant skin disorder characterized by widespread blistering and an ichthyotic erythroderma at birth that persist into adulthood. Histologically there is a diffuse epidermolytic degeneration in the lower spinous layer of the epidermis. Within a few weeks from birth, erythroderma and blister formation diminish and hyperkeratoses develop.
    Defects in KRT10 are a cause of ichthyosis annular epidermolytic (AEI) [MIM:607602]; also known as cyclic ichthyosis with epidermolytic hyperkeratosis. AEI is a skin disorder resembling bullous congenital ichthyosiform erythroderma. Affected individuals present with bullous ichthyosis in early childhood and hyperkeratotic lichenified plaques in the flexural areas and extensor surfaces at later ages. The feature that distinguishes AEI from BCIE is dramatic episodes of flares of annular polycyclic plaques with scale, which coalesce to involve most of the body surface and can persist for several weeks or even months.
  • Sequence similarities
    Belongs to the intermediate filament family.
  • Information by UniProt
  • Database links
  • Alternative names
    • BCIE antibody
    • BIE antibody
    • CK 10 antibody
    • CK-10 antibody
    • Cytokeratin-10 antibody
    • EHK antibody
    • K10 antibody
    • K1C10_HUMAN antibody
    • Keratin 10 antibody
    • Keratin 10 type I antibody
    • Keratin antibody
    • Keratin type i cytoskeletal 10 antibody
    • Keratin type I cytoskeletal 59 kDa antibody
    • Keratin-10 antibody
    • Keratin10 antibody
    • KPP antibody
    • KRT10 antibody
    • type I cytoskeletal 10 antibody
    see all

Images

  • Immunohistochemical analysis of Human skin labeling Cytokeratin 10 using ab183317 at a 1/100 dilution

  • Immunohistochemical analysis of Human skin labeling Cytokeratin 10 using ab183317 at a 1/100 dilution

  • Immunohistochemical analysis of Human skin squamous cell carcinoma labeling Cytokeratin 10 using ab183317 at a 1/100 dilution

  • Immunohistochemical analysis of Human cervical squamous cell carcinoma labeling Cytokeratin 10 using ab183317 at a 1/100 dilution.

References

ab183317 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

Application
Immunocytochemistry/ Immunofluorescence
Blocking step
Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: 25°C
Sample
Human Cell (skin)
Specification
skin
Permeabilization
No
Fixative
Formaldehyde
Username

Abcam user community

Verified customer

Submitted Nov 17 2014

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up